[{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IkT-148x","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"U.S. National Institute of Neurological Disease and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ U.S. National Institute of Neurological Disease and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase Therapeutics \/ U.S. National Institute of Neurological Disease and Stroke"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-001Pro","moa":"Abl kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"IkT-148009","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"IkT-148009","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib Succinate","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib Succinate","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inhibikase Therapeutics","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"14","companyTruncated":"Inhibikase Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inhibikase Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Inhibikase Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
